U.S. License Holder:
Eli Lilly
Date of License:
June-14-1996
Last Update:
Sep-30-2024
FDA-Approved Indications
HUMALOG (insulin lispro recombinant) is a rapid acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
aBLA / 505(b)(2) Activity
aBLA / 505(b)(2) Approved by FDA
Admelog®: Sanofi-Aventis (December-2017) Insulin Lispro (Authorized Generic) (Eli Lilly / ImClone) (March-2019)
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Admelog® (Sanofi) (July-2017)